Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion
- T C Kreutzer1,
- C S Alge1,
- A H Wolf1,
- D Kook1,
- J Burger1,
- R Strauss1,
- C Kunze2,
- C Haritoglou1,
- A Kampik1,
- S Priglinger1
- 1Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
- 2Department of Ophthalmology, Medical University, Innsbruck, Austria
- Dr S G Priglinger, Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Mathildenstr 8, 80336 Munich, Germany;
- Accepted 27 November 2007
- Published Online First 22 January 2008
Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.
Methods: A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.
Results: Patients presented at a mean age of 69 years (range 44–86). Mean duration of symptoms was 40 weeks (range 1–300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) μm, declining to 316 (41) μm at 6 months.
Conclusion: Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.
Part of this work has been presented at the 6th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT), Berlin, 2006.
Competing interests: None declared.